Home /
Chemotherapy – Charing Cross Hospital – Treatment Details
|
|
Description: |
Patients: This phase II study involved 63 patients with relapsed malignant pleural mesothelioma. Their median age was 59, ranging from 29 to 77 years old. The majority (93.6%) of patients were men.
Treatment: Patients were treated weekly with the chemotherapy drug vinorelbine. Toxicity: Grade 3/4 neutropenia was reported in 55% of patients; other, less common grade 3/4 toxicities were anemia, constipation, neuropathy, and phlebitis. Results: The median overall survival was 9.6 months. Correspondence: Dr. Justin Stebbing |